外周P-糖蛋白功能降低对痴呆患者地高辛浓度的影响
本研究通过回顾性病历审查和生理药代动力学(PBPK)建模,评估痴呆是否影响外周P-糖蛋白功能及地高辛浓度。结果显示非痴呆组(n=75)与痴呆组(n=72)地高辛浓度相似(0.64±0.31 vs 0.60±0.34 ng/mL),但PBPK模拟提示P-糖蛋白功能降低可显著增加地高辛AUC而不影响Cmax。
要点
- 痴呆与非痴呆患者临床实测地高辛浓度无统计学差异。
- PBPK模拟显示P-糖蛋白功能降低使地高辛AUC显著增加,Cmax不变。
- 评估P-糖蛋白功能影响时,地高辛AUC可能比谷浓度更敏感。
核心结论
- 临床实测地高辛浓度在痴呆与非痴呆患者间无统计学差异。
- 基于PBPK模拟,可能需要评估地高辛AUC以充分反映外周P-糖蛋白功能降低的影响。
研究设计与样本
- 回顾性病历审查比较非痴呆组(n=75)与痴呆组(n=72)的地高辛剂量和浓度。
- 建立PBPK模型模拟单次和多次62.5及125 μg/d地高辛给药下外周P-糖蛋白功能降低对浓度的影响。
主要发现
- 非痴呆组与痴呆组地高辛浓度均值±标准差分别为0.64±0.31和0.60±0.34 ng/mL,差值95%CI为-0.06至0.15。
- PBPK模拟显示P-糖蛋白功能降低显著增加地高辛AUC但不增加Cmax。
- 老年人多次125 μg/d给药下模拟P-糖蛋白功能降低2倍,末次给药间期AUC较基线增加(24.29±3.94 vs 17.04±3.46 ng/mL*h;95%CI 4.52至9.98),Cmax相似(1.38±0.20 vs 0.99±0.18 ng/mL;95%CI -2.33至3.13)。
临床怎么用
- 痴呆患者使用地高辛时,常规谷浓度监测可能不足以反映外周P-糖蛋白功能降低带来的暴露增加。
- 对痴呆患者进行地高辛治疗药物监测时,可考虑结合AUC评估以更全面判断暴露风险。
局限性
- 回顾性病历审查样本量有限(非痴呆75例、痴呆72例),可能影响统计效力。
- PBPK模拟结果为模型预测,需临床研究验证AUC与P-糖蛋白功能降低的关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Patients with Alzheimer's disease (AD), the most common form of dementia, have reduced P-glycoprotein (P-gp) function at the blood-brain barrier. However, the effect of AD on P-gp function in peripheral organs, and the impact on medication efficacy and toxicity is unknown. In this study, clinical chart review and physiologically based pharmacokinetic (PBPK) modelling were employed to determine whether disease-associated changes in P-gp could be assessed from clinically measured digoxin concentrations in patients without and with dementia. METHODS: A retrospective chart review was conducted to compare digoxin dose and concentrations between cohorts. A PBPK model was developed to simulate changes in digoxin concentrations at single and multiple 62.5 and 125 μg/d doses due to reduced P-gp function in peripheral organs. RESULTS: Digoxin concentrations were similar between the nondementia (n = 75) and dementia (n = 72) cohorts (mean ± standard deviation; 0.64 ± 0.31 and 0.60 ± 0.34 ng/mL, respectively; -0.06 to 0.15, 95% confidence interval of difference). PBPK simulations showed that reduced P-gp function resulted in a significant increase in digoxin exposure (AUC), but not in Cmax . For example, when a 2-fold reduction in P-gp function was simulated in older people following multiple 125 μg/d digoxin doses, the AUC over the last dosing interval was increased compared to baseline (24.29 ± 3.94 vs 17.04 ± 3.46 ng/mL*h; 4.52 to 9.98); however, Cmax was similar (1.38 ± 0.20 vs 0.99 ± 0.18 ng/mL; -2.33 to 3.13). CONCLUSION: Clinically measured digoxin concentrations were not statistically different in patients with dementia. Based on PBPK simulations, digoxin AUC may need to be evaluated to adequately assess the impact of reduced P-gp function in peripheral organs.
引用
- Ali I, Guidone D, Nicolazzo JA, et al. Impact of reduced P-glycoprotein function on digoxin concentrations in patients with dementia. Br J Clin Pharmacol. 2019. PMID: 31269278. doi:10.1111/bcp.14049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。